Cyclo Therapeutics (CYTH)
(Delayed Data from NSDQ)
$0.66 USD
-0.02 (-3.06%)
Updated Sep 10, 2024 03:59 PM ET
After-Market: $0.66 0.00 (0.00%) 7:34 PM ET
4-Sell of 5 4
F Value B Growth A Momentum D VGM
Cyclo Therapeutics, Inc. (CYTH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1.97 | $4.00 | $0.95 | 189.71% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Cyclo Therapeutics, Inc. comes to $1.97. The forecasts range from a low of $0.95 to a high of $4.00. The average price target represents an increase of 189.71% from the last closing price of $0.68.
Analyst Price Targets (3 )
Broker Rating
Cyclo Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Buy, representing 33.33% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CYTH.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.67 | 2.67 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/27/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Hold |
8/26/2024 | Ascendiant Capital Markets | Lucas Ward | Moderate Buy | Moderate Buy |
8/23/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.67 |
ABR (Last week) | 2.67 |
# of Recs in ABR | 3 |
Average Target Price | $1.97 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.15 |
CYTH FAQs
Cyclo Therapeutics, Inc. (CYTH) currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Cyclo Therapeutics, Inc. (CYTH) is $1.97. The current on short-term price targets is based on 1 reports.
The forecasts for Cyclo Therapeutics, Inc. (CYTH) range from a low of $.95 to a high of $4. The average price target represents a increase of $189.71 from the last closing price of $.68.
The current UPSIDE for Cyclo Therapeutics, Inc. (CYTH) is 189.71%
Based on short-term price targets offered by three analysts, the average price target for Cyclo Therapeutics, Inc. comes to $1.97. The forecasts range from a low of $0.95 to a high of $4.00. The average price target represents an increase of 189.71% from the last closing price of $0.68.